Development of companion diagnostics
Abstract
The goal of individualized and targeted treatment and precision medicine requires the assessment of potential therapeutic targets to direct treatment selection. The biomarkers used to direct precision medicine, often termed companion diagnostics, for highly targeted drugs have thus far been almost entirely based on in vitro assay of biopsy material. Molecular imaging companion diagnostics offer a number of features complementary to those from in vitro assay, including the ability to measure the heterogeneity of each patient’s cancer across the entire disease burden and to measure early changes in response to treatment. We discuss the use of molecular imaging methods as companion diagnostics for cancer therapy with the goal of predicting response to targeted therapy and measuring early (pharmacodynamic) response as an indication of whether the treatment has “hit” the target. We also discuss considerations for probe development for molecular imaging companion diagnostics, including both small-molecule probes and larger molecules such as labeled antibodies and related constructs. We then describe two examples where both predictive and pharmacodynamic molecular imaging markers have been tested in humans: endocrine therapy for breast cancer and human epidermal growth factor receptor type 2–targeted therapy. Lastly, the review closes with a summary of the items needed tomore »
- Authors:
-
- Univ. of Pennsylvania, Philadelphia, PA (United States). Perelman School of Medicine, Dept. of Radiology
- Publication Date:
- Research Org.:
- Univ. of Pennsylvania, Philadelphia, PA (United States)
- Sponsoring Org.:
- USDOE; U.S. Department of Defense (DoD)
- OSTI Identifier:
- 1344505
- Grant/Contract Number:
- SC0012476
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Seminars in Nuclear Medicine
- Additional Journal Information:
- Journal Volume: 46; Journal Issue: 1; Journal ID: ISSN 0001-2998
- Publisher:
- Elsevier
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 62 RADIOLOGY AND NUCLEAR MEDICINE
Citation Formats
Mankoff, David A., Edmonds, Christine E., Farwell, Michael D., and Pryma, Daniel A. Development of companion diagnostics. United States: N. p., 2015.
Web. doi:10.1053/j.semnuclmed.2015.09.002.
Mankoff, David A., Edmonds, Christine E., Farwell, Michael D., & Pryma, Daniel A. Development of companion diagnostics. United States. https://doi.org/10.1053/j.semnuclmed.2015.09.002
Mankoff, David A., Edmonds, Christine E., Farwell, Michael D., and Pryma, Daniel A. Sat .
"Development of companion diagnostics". United States. https://doi.org/10.1053/j.semnuclmed.2015.09.002. https://www.osti.gov/servlets/purl/1344505.
@article{osti_1344505,
title = {Development of companion diagnostics},
author = {Mankoff, David A. and Edmonds, Christine E. and Farwell, Michael D. and Pryma, Daniel A.},
abstractNote = {The goal of individualized and targeted treatment and precision medicine requires the assessment of potential therapeutic targets to direct treatment selection. The biomarkers used to direct precision medicine, often termed companion diagnostics, for highly targeted drugs have thus far been almost entirely based on in vitro assay of biopsy material. Molecular imaging companion diagnostics offer a number of features complementary to those from in vitro assay, including the ability to measure the heterogeneity of each patient’s cancer across the entire disease burden and to measure early changes in response to treatment. We discuss the use of molecular imaging methods as companion diagnostics for cancer therapy with the goal of predicting response to targeted therapy and measuring early (pharmacodynamic) response as an indication of whether the treatment has “hit” the target. We also discuss considerations for probe development for molecular imaging companion diagnostics, including both small-molecule probes and larger molecules such as labeled antibodies and related constructs. We then describe two examples where both predictive and pharmacodynamic molecular imaging markers have been tested in humans: endocrine therapy for breast cancer and human epidermal growth factor receptor type 2–targeted therapy. Lastly, the review closes with a summary of the items needed to move molecular imaging companion diagnostics from early studies into multicenter trials and into the clinic.},
doi = {10.1053/j.semnuclmed.2015.09.002},
journal = {Seminars in Nuclear Medicine},
number = 1,
volume = 46,
place = {United States},
year = {Sat Dec 12 00:00:00 EST 2015},
month = {Sat Dec 12 00:00:00 EST 2015}
}
Free Publicly Available Full Text
Publisher's Version of Record
Other availability
Search WorldCat to find libraries that may hold this journal
Cited by: 29 works
Citation information provided by
Web of Science
Web of Science
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
Cancer biomarkers
journal, February 2012
- Henry, N. Lynn; Hayes, Daniel F.
- Molecular Oncology, Vol. 6, Issue 2
Cancer biomarkers: a systems approach
journal, August 2006
- Hartwell, Lee; Mankoff, David; Paulovich, Amanda
- Nature Biotechnology, Vol. 24, Issue 8
Molecular Imaging Research in the Outcomes Era
journal, April 2007
- Mankoff, David A.; O’Sullivan, Finbarr; Barlow, William E.
- Academic Radiology, Vol. 14, Issue 4
How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy
journal, July 2015
- Farwell, Michael D.; Clark, Amy S.; Mankoff, David A.
- JAMA Oncology, Vol. 1, Issue 4
Positron Emission Tomography As an Imaging Biomarker
journal, July 2006
- Weber, Wolfgang A.
- Journal of Clinical Oncology, Vol. 24, Issue 20
Tumor Receptor Imaging
journal, June 2008
- Mankoff, David A.; Link, Jeanne M.; Linden, Hannah M.
- Journal of Nuclear Medicine, Vol. 49, Issue Suppl 2
Radioiodine Therapy for Thyroid Cancer in the Era of Risk Stratification and Alternative Targeted Therapies
journal, August 2014
- Pryma, Daniel A.; Mandel, Susan J.
- Journal of Nuclear Medicine, Vol. 55, Issue 9
Neuroendocrine tumours: the role of imaging for diagnosis and therapy
journal, December 2013
- van Essen, Martijn; Sundin, Anders; Krenning, Eric P.
- Nature Reviews Endocrinology, Vol. 10, Issue 2
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography
journal, June 2005
- Sasongko, L.; Link, J.; Muzi, M.
- Clinical Pharmacology & Therapeutics, Vol. 77, Issue 6
Prognostic Significance of [ 18 F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02
journal, May 2006
- Rischin, Danny; Hicks, Rodney J.; Fisher, Richard
- Journal of Clinical Oncology, Vol. 24, Issue 13
Molecular Imaging Biomarkers for Oncology Clinical Trials
journal, March 2014
- Mankoff, David A.; Pryma, Daniel A.; Clark, Amy S.
- Journal of Nuclear Medicine, Vol. 55, Issue 4
A historical perspective on the specific activity of radiopharmaceuticals: What have we learned in the 35years of the ISRC?
journal, April 2013
- Lapi, Suzanne E.; Welch, Michael J.
- Nuclear Medicine and Biology, Vol. 40, Issue 3
Update on Time-of-Flight PET Imaging
journal, December 2014
- Surti, S.
- Journal of Nuclear Medicine, Vol. 56, Issue 1
Antibody Vectors for Imaging
journal, May 2010
- Olafsen, Tove; Wu, Anna M.
- Seminars in Nuclear Medicine, Vol. 40, Issue 3
Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
journal, July 2011
- Linden, Hannah M.; Kurland, Brenda F.; Peterson, Lanell M.
- Clinical Cancer Research, Vol. 17, Issue 14
Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer
journal, June 2001
- Mortimer, Joanne E.; Dehdashti, Farrokh; Siegel, Barry A.
- Journal of Clinical Oncology, Vol. 19, Issue 11
PET/CT imaging in cancer: Current applications and future directions: PET-CT Imaging in Cancer
journal, June 2014
- Farwell, Michael D.; Pryma, Daniel A.; Mankoff, David A.
- Cancer, Vol. 120, Issue 22
Tumor-Specific Positron Emission Tomography Imaging in Patients: [ 18 F] Fluorodeoxyglucose and Beyond
journal, June 2007
- Mankoff, David A.; Eary, Janet F.; Link, Jeanne M.
- Clinical Cancer Research, Vol. 13, Issue 12
Assessing Tumor Response to Therapy
journal, April 2009
- Weber, Wolfgang A.
- Journal of Nuclear Medicine, Vol. 50, Issue Suppl 1
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
journal, April 2005
- Kelloff, Gary J.; Hoffman, John M.; Johnson, Bruce
- Clinical Cancer Research, Vol. 11, Issue 8
Role of PET quantitation in the monitoring of cancer response to treatment: review of approaches and human clinical trials
journal, July 2014
- Doot, Robert K.; McDonald, Elizabeth S.; Mankoff, David A.
- Clinical and Translational Imaging, Vol. 2, Issue 4
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
journal, March 2008
- Dehdashti, Farrokh; Mortimer, Joanne E.; Trinkaus, Kathryn
- Breast Cancer Research and Treatment, Vol. 113, Issue 3
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
journal, January 2012
- Kurland, Brenda F.; Gadi, Vijayakrishna K.; Specht, Jennifer M.
- EJNMMI Research, Vol. 2, Issue 1
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)
journal, September 2003
- Stroobants, S.; Goeminne, J.; Seegers, M.
- European Journal of Cancer, Vol. 39, Issue 14
[ 18 F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
journal, June 2009
- Ma, Wen Wee; Jacene, Heather; Song, Dongweon
- Journal of Clinical Oncology, Vol. 27, Issue 16
Imaging of Cell Proliferation: Status and Prospects
journal, June 2008
- Bading, James R.; Shields, Anthony F.
- Journal of Nuclear Medicine, Vol. 49, Issue Suppl 2
Hallmarks of Cancer: The Next Generation
journal, March 2011
- Hanahan, Douglas; Weinberg, Robert A.
- Cell, Vol. 144, Issue 5
Clinical studies of apoptosis and proliferation in breast cancer.
journal, March 1999
- Dowsett, M.; Archer, C.; Assersohn, L.
- Endocrine-related cancer
Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer
journal, February 2006
- Dowsett, Mitch; Smith, Ian E.; Ebbs, Steve R.
- Clinical Cancer Research, Vol. 12, Issue 3
Imaging Cellular Proliferation as a Measure of Response to Therapy
journal, July 2001
- Krohn, K. A.; Mankoff, D. A.; Eary, J. F.
- Journal of Clinical Pharmacology, Vol. 41, Issue 99
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
journal, November 1998
- Shields, Anthony F.; Grierson, John R.; Dohmen, Bernhard M.
- Nature Medicine, Vol. 4, Issue 11
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography
journal, March 2007
- Kenny, Laura; Coombes, R. Charles; Vigushin, David M.
- European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Issue 9
[ 18 F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung
journal, November 2008
- Sohn, Hee-Jung; Yang, You-Jung; Ryu, Jin-Sook
- Clinical Cancer Research, Vol. 14, Issue 22
A Phase II Study of 3′-Deoxy-3′- 18 F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688
journal, September 2015
- Kostakoglu, Lale; Duan, Fenghai; Idowu, Michael O.
- Journal of Nuclear Medicine, Vol. 56, Issue 11
Assessment of Cellular Proliferation in Tumors by PET Using 18 F-ISO-1
journal, January 2013
- Dehdashti, Farrokh; Laforest, Richard; Gao, Feng
- Journal of Nuclear Medicine, Vol. 54, Issue 3
Development of 18F-Labeled PET Probes for Imaging Cell Proliferation
journal, May 2013
- Sai, Kiran Kumar Solingapuram; Jones, Lynne A.; Mach, Robert H.
- Current Topics in Medicinal Chemistry, Vol. 13, Issue 8
Recent Advances in the Molecular Imaging of Programmed Cell Death: Part I—Pathophysiology and Radiotracers
journal, October 2012
- Blankenberg, Francis G.; Strauss, H. William
- Journal of Nuclear Medicine, Vol. 53, Issue 11
Imaging Caspase-3 Activation as a Marker of Apoptosis-Targeted Treatment Response in Cancer
journal, October 2014
- Chen, Delphine L.; Engle, Jacquelyn T.; Griffin, Elizabeth A.
- Molecular Imaging and Biology, Vol. 17, Issue 3
Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations
journal, February 2009
- Padhani, Anwar R.; Liu, Guoying; Mu-Koh, Dow
- Neoplasia, Vol. 11, Issue 2
Status of adjuvant endocrine therapy for breast cancer
journal, April 2014
- Schiavon, Gaia; Smith, Ian E.
- Breast Cancer Research, Vol. 16, Issue 2
Hormonal therapy in breast cancer: A model disease for the personalization of cancer care
journal, February 2012
- Puhalla, Shannon; Bhattacharya, Saveri; Davidson, Nancy E.
- Molecular Oncology, Vol. 6, Issue 2
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
journal, June 2010
- Ferlay, Jacques; Shin, Hai-Rim; Bray, Freddie
- International Journal of Cancer, Vol. 127, Issue 12
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
journal, June 2010
- Hammond, M. Elizabeth H.; Hayes, Daniel F.; Dowsett, Mitch
- Journal of Clinical Oncology, Vol. 28, Issue 16
Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance
journal, November 1992
- Spataro, V.; Price, K.; Goldhirsch, A.
- Annals of Oncology, Vol. 3, Issue 9
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
journal, September 1996
- Kuukasjärvi, T.; Kononen, J.; Helin, H.
- Journal of Clinical Oncology, Vol. 14, Issue 9
Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer
journal, June 2006
- Linden, Hannah M.; Stekhova, Svetlana A.; Link, Jeanne M.
- Journal of Clinical Oncology, Vol. 24, Issue 18
Comparative breast tumor imaging and comparative in vitro metabolism of 16α-[18F]Fluoroestradiol-17β and 16β-[18f]fluoromoxestrol in isolated hepatocytes
journal, January 1999
- Jonson, Stephanie D.; Bonasera, Thomas A.; Dehdashti, Farrokh
- Nuclear Medicine and Biology, Vol. 26, Issue 1
18F-Fluoroestradiol
journal, November 2007
- Sundararajan, Lavanya; Linden, Hannah M.; Link, Jeanne M.
- Seminars in Nuclear Medicine, Vol. 37, Issue 6
Characterization of the uptake of 16α-([18F]fluoro)-17β-estradiol in DMBA-induced mammary tumors
journal, January 1987
- Mathias, Carla J.; Welch, Michael J.; Katzenellenbogen, John A.
- International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, Vol. 14, Issue 1
Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-Fluorestradiol (FES)
journal, May 1997
- Mankoff, David A.; Tewson, Timothy J.; Eary, Janet F.
- Nuclear Medicine and Biology, Vol. 24, Issue 4
Interactions of 16α-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP)
journal, November 1999
- Tewson, T. J.; Mankoff, D. A.; Peterson, L. M.
- Nuclear Medicine and Biology, Vol. 26, Issue 8
Breast cancer: PET imaging of estrogen receptors.
journal, October 1988
- Mintun, M. A.; Welch, M. J.; Siegel, B. A.
- Radiology, Vol. 169, Issue 1
Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18 F-Fluoroestradiol
journal, February 2008
- Peterson, Lanell M.; Mankoff, David A.; Lawton, Thomas
- Journal of Nuclear Medicine, Vol. 49, Issue 3
Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by 18 F-Fluoroestradiol PET
journal, September 2011
- Kurland, Brenda F.; Peterson, Lanell M.; Lee, Jean H.
- Journal of Nuclear Medicine, Vol. 52, Issue 10
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
journal, June 2015
- Jeselsohn, Rinath; Buchwalter, Gilles; De Angelis, Carmine
- Nature Reviews Clinical Oncology, Vol. 12, Issue 10
A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
journal, October 2013
- Peterson, Lanell M.; Kurland, Brenda F.; Schubert, Erin K.
- Molecular Imaging and Biology, Vol. 16, Issue 3
PET imaging of oestrogen receptors in patients with breast cancer
journal, October 2013
- van Kruchten, Michel; de Vries, Elisabeth G. E.; Brown, Myles
- The Lancet Oncology, Vol. 14, Issue 11
Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy
journal, June 2015
- van Kruchten, Michel; Glaudemans, Andor W. J. M.; de Vries, Erik F. J.
- European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, Issue 11
Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer
journal, January 2015
- Humbert, O.; Cochet, A.; Coudert, B.
- The Oncologist, Vol. 20, Issue 2
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
journal, October 2010
- Di Leo, Angelo; Jerusalem, Guy; Petruzelka, Lubos
- Journal of Clinical Oncology, Vol. 28, Issue 30
Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
journal, November 2014
- van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.
- Cancer Discovery, Vol. 5, Issue 1
17β-Estradiol Augments 18 F-FDG Uptake and Glycolysis of T47D Breast Cancer Cells via Membrane-Initiated Rapid PI3K–Akt Activation
journal, October 2010
- Ko, Bong-Ho; Paik, Jin-Young; Jung, Kyung-Ho
- Journal of Nuclear Medicine, Vol. 51, Issue 11
Abstract P4-01-02: The role of FLT PET early assessment of response to endocrine therapy for early stage breast cancer
conference, March 2014
- Linden, Hm; Kurland, Bf; Link, Jm
- Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX, Poster Session Abstracts
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
journal, July 2015
- Turner, Nicholas C.; Ro, Jungsil; André, Fabrice
- New England Journal of Medicine, Vol. 373, Issue 3
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
journal, November 2013
- Wolff, Antonio C.; Hammond, M. Elizabeth H.; Hicks, David G.
- Journal of Clinical Oncology, Vol. 31, Issue 31
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
journal, October 1996
- Carlomagno, C.; Perrone, F.; Gallo, C.
- Journal of Clinical Oncology, Vol. 14, Issue 10
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend
journal, January 2007
- Ferretti, Gianluigi; Felici, Alessandra; Papaldo, Paola
- Current Opinion in Obstetrics & Gynecology, Vol. 19, Issue 1
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
journal, July 1992
- Gusterson, B. A.; Gelber, R. D.; Goldhirsch, A.
- Journal of Clinical Oncology, Vol. 10, Issue 7
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
journal, January 1987
- Slamon, D.; Clark, G.; Wong, S.
- Science, Vol. 235, Issue 4785
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
journal, May 1989
- Slamon, D.; Godolphin, W.; Jones, L.
- Science, Vol. 244, Issue 4905
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
journal, March 2001
- Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven
- New England Journal of Medicine, Vol. 344, Issue 11
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
journal, October 2005
- Romond, Edward H.; Perez, Edith A.; Bryant, John
- New England Journal of Medicine, Vol. 353, Issue 16
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
journal, January 2012
- Baselga, José; Cortés, Javier; Kim, Sung-Bae
- New England Journal of Medicine, Vol. 366, Issue 2
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
journal, November 2012
- Verma, Sunil; Miles, David; Gianni, Luca
- New England Journal of Medicine, Vol. 367, Issue 19
Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue
journal, July 2012
- Potts, Steven J.; Krueger, Joseph S.; Landis, Nicholas D.
- Laboratory Investigation, Vol. 92, Issue 9
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
journal, October 2007
- Santinelli, Alfredo; Pisa, Eleonora; Stramazzotti, Daniela
- International Journal of Cancer, Vol. 122, Issue 5
Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy
journal, January 2010
- Capala, Jacek; Bouchelouche, Kirsten
- Current Opinion in Oncology, Vol. 22, Issue 6
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
journal, March 2010
- Dijkers, E. C.; Oude Munnink, T. H.; Kosterink, J. G.
- Clinical Pharmacology & Therapeutics, Vol. 87, Issue 5
Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
journal, May 2012
- Tolmachev, Vladimir; Tran, Thuy A.; Rosik, Daniel
- Journal of Nuclear Medicine, Vol. 53, Issue 6
Novel Methods and Tracers for Breast Cancer Imaging
journal, July 2013
- Linden, Hannah M.; Dehdashti, Farrokh
- Seminars in Nuclear Medicine, Vol. 43, Issue 4
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
journal, September 2013
- Tamura, K.; Kurihara, H.; Yonemori, K.
- Journal of Nuclear Medicine, Vol. 54, Issue 11
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
journal, May 2004
- Smith-Jones, Peter M.; Solit, David B.; Akhurst, Timothy
- Nature Biotechnology, Vol. 22, Issue 6
Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer
journal, January 2013
- Beylergil, Volkan; Morris, Patrick G.; Smith-Jones, Peter M.
- Nuclear Medicine Communications, Vol. 34, Issue 12
Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein
journal, March 2013
- Orlova, Anna; Jonsson, Andreas; Rosik, Daniel
- Journal of Nuclear Medicine, Vol. 54, Issue 6
Radiolabeling of HER2-specific Affibody® molecule with F-18
journal, September 2008
- Kiesewetter, Dale O.; Krämer-Marek, Gabriela; Ma, Ying
- Journal of Fluorine Chemistry, Vol. 129, Issue 9
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
journal, May 2010
- Baum, R. P.; Prasad, V.; Muller, D.
- Journal of Nuclear Medicine, Vol. 51, Issue 6
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111 In-ABY-025 Affibody Molecule
journal, March 2014
- Sörensen, Jens; Sandberg, Dan; Sandström, Mattias
- Journal of Nuclear Medicine, Vol. 55, Issue 5
89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft
journal, February 2010
- Oude Munnink, Thijs H.; Korte, Maarten A. de; Nagengast, Wouter B.
- European Journal of Cancer, Vol. 46, Issue 3
89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
journal, July 2014
- Gaykema, S. B. M.; Schroder, C. P.; Vitfell-Rasmussen, J.
- Clinical Cancer Research, Vol. 20, Issue 15
HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
journal, August 2013
- Groheux, D.; Giacchetti, S.; Hatt, M.
- British Journal of Cancer, Vol. 109, Issue 5
HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy
journal, March 2014
- Humbert, Olivier; Cochet, Alexandre; Riedinger, Jean-Marc
- European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Issue 8
18 F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
journal, October 2013
- Gebhart, Geraldine; Gámez, Cristina; Holmes, Eileen
- Journal of Nuclear Medicine, Vol. 54, Issue 11
TBCRC 008: Early Change in 18 F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer
journal, December 2014
- Connolly, Roisin M.; Leal, Jeffrey P.; Goetz, Matthew P.
- Journal of Nuclear Medicine, Vol. 56, Issue 1
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
journal, December 2014
- Coudert, Bruno; Pierga, Jean-Yves; Mouret-Reynier, Marie-Ange
- The Lancet Oncology, Vol. 15, Issue 13
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)
journal, August 2015
- Lin, Nancy U.; Guo, Hao; Yap, Jeffrey T.
- Journal of Clinical Oncology, Vol. 33, Issue 24
PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).
journal, May 2014
- Gebhart, Geraldine; Lamberts, Laetitia E.; Garcia, Camilo
- Journal of Clinical Oncology, Vol. 32, Issue 15_suppl
How Imaging Can Impact Clinical Trial Design: Molecular Imaging as a Biomarker for Targeted Cancer Therapy
journal, January 2015
- Mankoff, David A.; Farwell, Michael D.; Clark, Amy S.
- The Cancer Journal, Vol. 21, Issue 3
Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
journal, December 2012
- McShane, Lisa M.; Hayes, Daniel F.
- Journal of Clinical Oncology, Vol. 30, Issue 34
Works referencing / citing this record:
Intact Transition Epitope Mapping – Targeted High-Energy Rupture of Extracted Epitopes (ITEM-THREE)
journal, May 2019
- Danquah, Bright D.; Röwer, Claudia; Opuni, Kwabena F. M.
- Molecular & Cellular Proteomics, Vol. 18, Issue 8
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
journal, August 2018
- Brand, Christian; Sadique, Ahmad; Houghton, Jacob L.
- EJNMMI Research, Vol. 8, Issue 1
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
journal, August 2018
- Brand, Christian; Sadique, Ahmad; Houghton, Jacob L.
- EJNMMI Research, Vol. 8, Issue 1
Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology.
journalarticle, January 2019
- Kurhanewicz, John; Vigneron, Daniel B.; Ardenkjaer-Larsen, Jan Henrik
- Elsevier BV
A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors
journal, January 2017
- Yun, Misun; Kim, Dong-Yeon; Lee, Joong-jae
- Theranostics, Vol. 7, Issue 10